Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

First Posted Date
2011-09-28
Last Posted Date
2018-01-03
Lead Sponsor
Stanford University
Target Recruit Count
33
Registration Number
NCT01442714
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

First Posted Date
2011-09-26
Last Posted Date
2019-03-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
77
Registration Number
NCT01440582
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

First Posted Date
2011-09-14
Last Posted Date
2022-03-10
Lead Sponsor
University of California, Davis
Target Recruit Count
16
Registration Number
NCT01433965
Locations
🇺🇸

University of California Davis, Sacramento, California, United States

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

First Posted Date
2011-09-05
Last Posted Date
2019-10-08
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
26
Registration Number
NCT01429025
Locations
🇺🇸

Iowa Lutheran Hospital, Des Moines, Iowa, United States

🇺🇸

Siouxland Hematology-Oncology, Sioux City, Iowa, United States

🇺🇸

Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States

and more 14 locations

Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Lenalidomide
First Posted Date
2011-08-23
Last Posted Date
2015-07-23
Lead Sponsor
University Hospital, Bordeaux
Target Recruit Count
13
Registration Number
NCT01421927
Locations
🇫🇷

CHU Bordeaux - Hôpital Haut-Lévêque, Pessac, France

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

First Posted Date
2011-08-22
Last Posted Date
2021-11-16
Lead Sponsor
MorphoSys AG
Target Recruit Count
91
Registration Number
NCT01421186
Locations
🇦🇹

AKH (Allgemeines Krankenhaus der Stadt Wien), Abteilung für Klinische Onkologie, Universitätsklinik für Innere Medizin I, Vienna, Austria

🇩🇪

Medizinische Klinik II, Abt. Hämatologie, Onkologie,, Tübingen, Germany

🇩🇪

Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie, Würzburg, Germany

and more 7 locations

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

First Posted Date
2011-08-18
Last Posted Date
2017-07-27
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
3
Registration Number
NCT01419795
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

First Posted Date
2011-08-12
Last Posted Date
2024-12-04
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
373
Registration Number
NCT01415752
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

Mount Sinai Hospital Medical Center, Chicago, Illinois, United States

and more 413 locations

A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma

First Posted Date
2011-08-09
Last Posted Date
2015-08-11
Lead Sponsor
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Target Recruit Count
36
Registration Number
NCT01412307
Locations
🇮🇹

Hematology Oncology and Stem Cell Transplantation Unit , IRCCS Fondazione "G.Pascale", Naples, Italy

Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus

Phase 4
Completed
Conditions
Cutaneous Lupus
Interventions
Drug: Lenalidomide
First Posted Date
2011-08-03
Last Posted Date
2011-08-03
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Target Recruit Count
15
Registration Number
NCT01408199
Locations
🇪🇸

Vall D'Hebron Hospital, Barcelona, Spain

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy